Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Alirocumab (Praluent) vs Rosuvastatin (Crestor): Rosuvastatin (Crestor) has the stronger overall evidence (4.5 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Rosuvastatin (Crestor) wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Alirocumab (Praluent) and Rosuvastatin (Crestor) have evidence — compare verdict strength side-by-side.
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
any
Subcutaneous prefilled pen/syringe (alirocumab)
5–20 mg once daily (up to 40 mg in selected high-risk patients), titrated to LDL/ApoB targets — under a clinician. A prescription drug; not a self-directed supplement regimen.
any
Oral tablet (rosuvastatin 5–20 mg)
Within weeks
Months to years
Years
At each injection
2–4 weeks
Months to years
1–2 years
Throughout use
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine (2018) · Rct · n=18924
ODYSSEY OUTCOMES randomized trial of ~18,900 patients 1–12 months after acute coronary syndrome on intensive statins
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
The New England journal of medicine (2015) · Rct · n=2341
ODYSSEY LONG TERM randomized trial in high-cardiovascular-risk patients on maximally tolerated statins
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
European heart journal (2015) · Rct · n=735
Pooled ODYSSEY FH I and FH II randomized trials in 735 heterozygous familial-hypercholesterolemia patients
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The New England journal of medicine (2008) · Rct · n=17802
JUPITER randomized placebo-controlled primary-prevention trial (~17,800 participants with normal LDL but elevated hsCRP)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet (London, England) (2010) · Meta analysis
Meta-analysis of ~170,000 participants across 26 randomized statin trials
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
JAMA (2006) · Open label · n=507
ASTEROID open-label IVUS trial (507 enrolled; 349 with evaluable serial imaging)
Rosuvastatin (Crestor) has a higher evidence score (4.5/10 vs 4.5/10) and wins in 1 of 3 categories.
For support heart health, Alirocumab (Praluent) has a higher relevance score (80 vs 78).
No known interactions between Alirocumab (Praluent) and Rosuvastatin (Crestor) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.